ALLERGAN PLC (NYSE:AGN) Files An 8-K Results of Operations and Financial Condition

ALLERGAN PLC (NYSE:AGN) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Results of Operations and Financial Condition.
Story continues below

On January 29, 2019, Allergan plc (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2018. A copy of the press release reporting the financial results of the Company is attached to this report as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including the exhibits) is furnished to Item 2.02 and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 2.02 Financial Statements and Exhibits.

Allergan plc Exhibit
EX-99.1 2 tv511761_ex99-1.htm EXIHBIT 99.1 Exhibit 99.1 Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results – Full-Year 2018 GAAP Net Revenues of $15.8 Billion; Q4 2018 GAAP Net Revenues of $4.1 Billion – – Full-Year 2018 GAAP Loss Per Share of $15.26; Non-GAAP Performance Net Income Per Share of $16.69 – – Q4 2018 GAAP Loss Per Share of $12.83; Non-GAAP Performance Net Income Per Share of $4.29 – – Q4 2018 GAAP Operating Loss of $5.38 Billion; Non-GAAP Operating Income of $1.92 Billion – – Full-Year and Q4 2018 GAAP Net Revenue Driven by Growth in Top Promoted Products Including BOTOX®,…
To view the full exhibit click here

An ad to help with our costs